WebFedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis. It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2). It was approved by the FDA on 16 August 2024. Myelofibrosis is a … WebJan 14, 2024 · Uses for fedratinib. Fedratinib is used to treat intermediate-2 or high-risk myelofibrosis, including primary or secondary (post-polycythemia vera and post-essential thrombocythemia) myelofibrosis. Myelofibrosis is a life-threatening bone marrow problem which is manifested by the following symptoms: enlarged spleen (splenomegaly), severe ...
Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in ...
WebNo lower-cost generic available. No lower-cost generic available. No lower-cost generic available. Ratings & Reviews: Fedratinib has an average rating of 1.0 out of 10 from a … WebInrebic 100mg. 60 capsules at Walgreens. $ 12,551. BIN PCN Group Member ID. 015995 GDC DR33 DDR297708. Coupon • Last updated Apr 6. This is not insurance. textsms Text. email. Rhopressa (Netarsudil) is used to treat open-angle glaucoma and high pressure … common binomial factor tutorial
Fedratinib - Wikipedia
WebFedratinib (INREBIC) is an oral, selective kinase inhibitor with activity against mutant and wild-type JAK2 and FLT3. Fedratinib is approved in the United States, Canada, … WebSMC No. SMC2462. Fedratinib (Inrebic®) for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post … WebDescription. Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and … common biochemical tests